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Background: Although practice guidelines recommend that perioper-
ative b-blockade be initiated at least several days to weeks before
noncardiac surgery is performed, the minimum required period of
preoperative therapy is unclear.
Methods: Population-based administrative databases were used to
conduct a cohort study of 48,103 patients aged  66 years who un-
derwent major elective noncardiac surgery in Ontario, Canada and
received preoperative b-blocker therapy. We used multivariable logistic
regression to determine the association of duration of preoperative
b-blocker treatment (classiﬁed as 1-7 days, 8-30 days, and  31 days)
with 30-day mortality, 30-day myocardial infarction (MI), 30-day
ischemic stroke, and 1-year mortality.
Results: The duration of preoperative b-blocker treatment was 1-7
days in 1105 patients (2.3%), 8-30 days in 2639 patients (5.5%), and
 31 days in 44,269 patients (92.0%). Compared with  31 days of
preoperative therapy, 1-7 days of therapy was associated with
increased 30-day mortality (odds ratio [OR], 1.49; 95% conﬁdenceReceived for publication June 27, 2013. Accepted October 15, 2013.
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ORESUME
Introduction : Bien que les lignes directrices sur la pratique recom-
mandent d’entreprendre le bêtablocage perioperatoire au moins plu-
sieurs jours à plusieurs semaines avant la realisation de la chirurgie non
cardiaque, la periode minimale requise de traitement preoperatoire
n’est pas elucidee.
Methodes : Les bases de donnees administratives fondees sur la
population ont ete utilisees pour mener une etude de cohorte de
48 103 patients âges  66 ans qui ont subi une chirurgie non car-
diaque majeure et non urgente en Ontario, au Canada, et qui ont reçu
un traitement bêtabloquant en phase preoperatoire. Nous avons utilise
la regression logistique multivariee pour determiner le lien entre la
duree du traitement bêtabloquant en phase preoperatoire (classiﬁee
comme allant de 1 à 7 jours, de 8 à 30 jours et  31 jours), et la
mortalite à 30 jours, l’infarctus du myocarde (IM) à 30 jours, l’accident
vasculaire cerebral ischemique à 30 jours et la mortalite à 1 an.
Resultats : La duree du traitement bêtabloquant en phase preoperatoire
a ete de 1 à 7 jours chez 1105 patients (2,3 %), de 8 à 30 jours chezPostoperative cardiac complications affect 2% of the 234
million individuals undergoing surgery worldwide every
year.1,2 One of the earliest recommended approaches for
preventing these events was perioperative b-blockade.3 These
recommendations were largely driven by positive results in 2
initial randomized controlled trials (RCTs),4,5 especially the
Dutch Echocardiographic Cardiac Risk Evaluation ApplyingStress Echocardiography (DECREASE)-I trial showing sub-
stantial cardiac risk reduction with b-blockade.5
Notably, these initial results were not replicated by subse-
quent RCTs.6-8 Most recently, the Perioperative Ischemic
Evaluation (POISE) trial demonstrated that although b-blockers
reduced perioperative myocardial infarction (MI), this beneﬁt
was offset by increased mortality, stroke, and hypotension.9
Some experts have attributed the discrepancy between early
ﬁndings and more recent research to differences in the duration
of preoperative therapy.10 In the DECREASE-I trial,5 partici-
pants received  7 days of preoperative therapy, whereas
patients in recent RCTs began therapy between 2 hours and
1 day before surgery.6-9 Current guidelines therefore recom-
mend initiating b-blockade “well before a planned procedure
with careful titration.”11 Nonetheless, there are few studiespen access under CC BY-NC-ND license.
interval [CI], 1.03-2.16; P ¼ 0.03], whereas 8-30 days of therapy was
not (OR, 0.95; 95% CI, 0.69-1.31; P ¼ 0.77). One to 7 days of pre-
operative therapy was not signiﬁcantly associated with 1-year mortality
(OR, 1.06; 95% CI, 0.84-1.35; P ¼ 0.62), 30-day MI (OR, 1.26; 95% CI,
0.92-1.71; P ¼ 0.15), or 30-day ischemic stroke (OR, 1.37; 95% CI,
0.64-2.94; P ¼ 0.41).
Conclusions: Initiation of b-blocker therapy 1-7 days before noncar-
diac surgery is associated with increased 30-day mortality. The ﬁnd-
ings merit further evaluation by randomized trials.
2639 patients (5,5 %) et  31 jours chez 44 269 patients (92,0 %).
Comparativement au traitement preoperatoire  31 jours, le traite-
ment de 1 à 7 jours a ete associe à une augmentation de la mortalite à
30 jours (ratio d’incidence approche [RIA], 1,49; intervalle de con-
ﬁance [IC] à 95 %, 1,03-2,16; P ¼ 0,03), tandis que le traitement de 8
à 30 jours ne l’a pas ete (RIA, 0,95; IC à 95 %, 0,69-1,31; P ¼ 0,77). Le
traitement de 1 à 7 jours n’a pas ete signiﬁcativement associe à la
mortalite à 1 an (RIA, 1,06; IC à 95 %, 0,84-1,35; P ¼ 0,62), à l’IM à
30 jours (RIA, 1,26; IC à 95 %, 0.92-1.71; P ¼ 0,15) ou à l’accident
vasculaire cerebral ischemique à 30 jours (RIA, 1,37; IC à 95 %, 0,64-
2,94; P ¼ 0,41).
Conclusions : L’introduction du traitement bêtabloquant de 1 à 7 jours
avant la chirurgie non cardiaque est associee à une augmentation de
la mortalite à 30 jours. Les resultats meritent une evaluation plus
approfondie à partir d’essais aleatoires.
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treatment inﬂuences outcomes.12,13 We therefore conducted
a population-based study to determine the association of
duration of preoperative b-blocker treatment with mor-
tality, MI, and acute ischemic stroke after major noncardiac
surgery.Methods
A more detailed description of the methods is presented in
the online Supplemental Methods section. After research ethics
approval from Sunnybrook Health Sciences Centre, we con-
ducted a retrospective cohort study using the following linked
population-based administrative databases: the Discharge Ab-
stract Database of the Canadian Institute for Health Infor-
mation, the Ontario Health Insurance Plan database, the
Registered Persons Database, and the Ontario Drug Beneﬁt
database.14-18 The cohort included all Ontario residents aged
 66 years who underwent any 1 of 16 prespeciﬁed elective
intermediate- to high-risk noncardiac surgical procedures be-
tween April 1, 2003 and March 31, 200911,19,20 and received
preoperative b-blocker therapy. Such therapy was deﬁned by
outpatient prescriptions for oral b-blockers (excluding sotalol,
carvedilol, or nadolol) within 100 days before surgery. The
included operations were abdominal aortic aneurysm repair,
carotid endarterectomy, peripheral vascular bypass, hip
replacement, knee replacement, large bowel resection, partial
liver resection, pancreatoduodenectomy, pneumonectomy,
pulmonary lobectomy, gastrectomy, esophagectomy, abdom-
inal hysterectomy, radical prostatectomy, nephrectomy, and
cystectomy. Individuals were classiﬁed as having received (1)
1-7 days, (2) 8-30 days, or (3)  31 days of preoperative
b-blocker therapy.13 We used the prescription closest to the
surgical procedure to determine each individual’s daily
b-blocker dose.
The primary outcome was 30-day mortality, and secondary
outcomes included 30-day MI, 30-day acute ischemic stroke,
and 1-year mortality. Other covariates included demographic
information from the Registered Persons Database, as well as
the presence of diabetes and hypertension, which we identiﬁed
using validated algorithms.15,17 The Ontario Health Insur-
ance Plan database was used to identify anyone who required
dialysis before surgery. Using the Discharge Abstract Data-
base, we identiﬁed other comorbidities, including coronaryartery disease, heart failure, cerebrovascular disease, peripheral
vascular disease, pulmonary disease, renal insufﬁciency, and
malignancy.21 Perioperative cardiac risk was estimated using
the Revised Cardiac Risk Index.22 The Ontario Drug Beneﬁt
database was used to ascertain preoperative prescriptions for
calcium channel blockers, angiotensin-converting-enzyme
inhibitors, angiotensin receptor blockers, diuretics, thieno-
pyridines, warfarin, and statins.
All analyses were performed using SAS, version 9.2 (SAS
Institute, Cary, NC). A 2-tailed P value < 0.05 was used to
deﬁne statistical signiﬁcance. We ﬁrst used appropriate tests
(1-way analysis of variance, Kruskal-Wallis test, c2 test) to
compare the characteristics and outcomes of patients
receiving differing durations of preoperative b-blockade. We
excluded carotid endarterectomy procedures when perform-
ing analyses related to acute ischemic stroke. Multivariable
logistic regression modelling was used separately to determine
the adjusted association between duration of b-blocker
treatment and 30-day mortality, 1-year mortality, 30-day MI,
and 30-day ischemic stroke.9,23,24 Subgroup analyses were
performed based on age, sex, and surgical procedure. We also
repeated the analyses separately within subgroups receiving
either long-acting b-blocker formulations (ie, atenolol, biso-
prolol, metoprolol succinate) or other b-blocker formula-
tions. Additionally, multivariable analyses were repeated after
categorizing the duration of b-blocker therapy as 1-7 days,
8-14 days, 15-21 days, 22-30 days, and  31 days. We also
used restricted cubic splines to model the association between
the duration of preoperative b-blocker treatment and 30-day
mortality.25Results
The cohort included 48,013 individuals: 2.3% (n¼ 1105)
began b-blocker therapy within 1-7 days before surgery, 5.5%
(n ¼ 2639) began therapy between 8 and 30 days before
surgery, and 92.0% (n ¼ 44,269) began therapy  31 days
before surgery. The 3 categories differed with respect to many
perioperative characteristics (Table 1), as well as the type
(Supplemental Table S1) and daily dose (Supplemental
Table S2) of b-blocker. Nonetheless, daily dosage did not
differ signiﬁcantly between individuals receiving 1-7 days vs
8-30 days of preoperative b-blocker therapy (Supplemental
Table S2).
Table 1. Characteristics of study cohort*
Duration of preoperative b-blocker therapy
P value
1-7 days before surgery
(n ¼ 1105) (%)
8-30 days before surgery
(n ¼ 2639) (%)
 31 days before surgery
(n ¼ 44,269) (%)
Demographics
Female sex 525 (47.5) 1351 (51.2) 23,169 (52.3) 0.004
Age (y), mean (SD) 75.3 (5.9) 75.4 (6.1) 75.0 (5.9) 0.002
Comorbid disease
Coronary artery disease 176 (15.9) 429 (16.3) 11,187 (25.3) < 0.001
Congestive heart failure 26 (2.4) 68 (2.6) 2357 (5.3) < 0.001
Cerebrovascular disease 35 (3.2) 101 (3.8) 1879 (4.2) 0.13
Peripheral vascular disease 161 (14.6) 438 (16.6) 5494 (12.4) < 0.001
Atrial ﬁbrillation 33 (3.0) 99 (3.8) 3253 (7.3) < 0.001
Hypertension 925 (83.7) 2231 (84.5) 40,901 (92.4) < 0.001
Diabetes mellitus 377 (34.1) 763 (28.9) 13,978 (31.6) 0.003
Pulmonary disease 66 (6.0) 165 (6.3) 2674 (6.0) 0.90
Renal disease 29 (2.6) 93 (3.5) 2231 (5.0) < 0.001
Malignancy
Primary 381 (34.5) 653 (24.7) 11,204 (25.3) < 0.001
Metastatic 82 (7.4) 153 (5.8) 2226 (5.0)
Procedure
AAA repair 84 (7.6) 278 (10.5) 2704 (6.1)
Carotid endarterectomy 28 (2.5) 85 (3.2) 1770 (4.0)
Peripheral vascular bypass 64 (5.8) 129 (4.9) 2092 (4.7)
Total hip replacement 173 (15.7) 521 (19.7) 8565 (19.3)
Total knee replacement 314 (28.4) 876 (33.2) 15,191 (34.3)
Large bowel surgery 231 (20.9) 339 (12.8) 6506 (14.7)
Liver resection or
pancreatoduodenectomy
16 (1.5) 17 (0.6) 370 (0.8) < 0.001
Lung resection 25 (2.3) 74 (2.8) 997 (2.3)
Gastrectomy or esophagectomy 24 (2.2) 31 (1.2) 696 (1.6)
Abdominal hysterectomy 80 (7.2) 162 (6.1) 2802 (6.3)
Radical prostatectomy 27 (2.4) 54 (2.0) 990 (2.2)
Nephrectomy 27 (2.4) 41 (1.6) 1160 (2.6)
Cystectomy 12 (1.1) 32 (1.2) 426 (1.0)
Revised Cardiac Risk Indexy
1 point 374 (33.8) 1017 (38.5) 15,663 (35.4)
2 points 422 (38.2) 1028 (39.0) 16,157 (36.5) < 0.001
3 points 238 (21.5) 444 (16.8) 8301 (18.8)
 4 points 71 (6.4) 150 (5.7) 4148 (9.4)
Preoperative medications
ACE inhibitor 435 (39.4) 1027 (38.9) 1952 (44.1) < 0.001
ARB 177 (16.0) 442 (16.7) 814 (18.4) < 0.001
Calcium channel blocker 150 (13.6) 417 (15.8) 763 (17.2) < 0.001
Furosemide 101 (9.1) 205 (7.8) 559 (12.6) < 0.001
Thiazide diuretic 265 (24.0) 648 (24.6) 1133 (25.6) < 0.001
Statin 471 (42.6) 1146 (43.4) 2234 (50.4) < 0.001
Thienopyridine 39 (3.5) 93 (3.5) 353 (8.0) < 0.001
Warfarin 62 (5.6) 186 (7.0) 538 (12.1) < 0.001
AAA, abdominal aortic aneurysm; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; SD, standard deviation
* Values are expressed as number (percentage) unless indicated otherwise
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Duration of Preoperative b-BlockadeThe overall event rates were 1.7% (n ¼ 839) for 30-day
mortality, 6.2% (n ¼ 2954) for 1-year mortality, and 2.9%
(n ¼ 1380) for 30-day MI (Fig. 1; Supplemental Table S3).
Among the 46,130 individuals who underwent a surgical
procedure besides carotid endarterectomy, 0.3% (n ¼ 149)
experienced 30-day acute ischemic strokes. Compared with
starting b-blocker treatment  31 days before surgery
(Fig. 1), the unadjusted risk of 30-day mortality was signiﬁ-
cantly higher (P ¼ 0.005) among individuals who started
therapy 1-7 days before surgery, whereas their unadjusted risk
of 1-year mortality approached statistical signiﬁcance (P ¼
0.06). Their unadjusted risks of 30-day MI (P ¼ 0.14) and
30-day ischemic stroke (P ¼ 0.50) were not signiﬁcantly
different.
After multivariable risk adjustment (Table 2), initiation of
b-blocker therapy 1-7 days before surgery was associated withincreased 30-day mortality (odds ratio [OR] 1.49; 95%
conﬁdence interval [CI], 1.03-2.16; P ¼ 0.03), whereas
initiation between 8 and 30 days before surgery was not (OR,
0.95; 95% CI, 0.69-1.31; P ¼ 0.77). There was no statisti-
cally signiﬁcant association between duration of b-blocker
treatment and other outcomes (Table 2). Kaplan-Meier curves
suggested that the additional deaths associated with 1-7 days
of preoperative b-blocker therapy were largely observed early
after surgery (Fig. 2).
There were no subgroup effects based on age, surgical
procedure, or b-blocker type. The relationship between the
duration of preoperative b-blocker treatment and 30-day
mortality remained similar if treatment duration was
modelled using restricted cubic splines (Supplemental
Fig. S1), or as a 5-level categorical variable (Supplemental
Table S4).
Figure 1. Unadjusted event rates for speciﬁc postoperative complications based on the duration of b-blocker treatment before surgery. The P values
for unadjusted statistical comparisons of proportions with these speciﬁc complications are presented in red text above their respective columns.
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In this population-based study, initiation of oral b-blocker
therapy within 1-7 days before major elective noncardiac
surgery was associated with increased 30-day mortality. By
comparison, once 8-30 days had elapsed after initiation of
therapy, the risk of 30-day mortality was not signiﬁcantly
different from that in individuals receiving b-blockers for
longer periods. Notably, the timing of preoperative b-blocker
initiation appeared to inﬂuence only short-term postoperative
mortality. Recent initiation of b-blockade had no signiﬁcant
association with 1-year mortality, and additional deaths
associated with recent b-blocker initiation were largely
observed during the immediate postoperative period.
There are several possible explanations for the increased
30-day mortality among patients who started b-blocker ther-
apy 1-7 days before surgery. First, the decreased time window
may not allow for adequate dose titration to simultaneously
achieve reasonable heart rate control while minimizing hy-
potension,13 although we did not observe differences in b-
blocker dosage between individuals receiving 1-7 days vs 8-30
days of preoperative therapy. Second, cardiovascular effects of
acute vs chronic b-blocker therapy may differ, as previously
demonstrated in patients receiving b-blockers for treatment ofTable 2. Adjusted association of timing of b-blocker initiation with clinical o
Duration of preoperative
b-blocker therapy 30-day mortality 30-day
1-7 days before surgery
(n ¼ 1105)
OR, 1.49 95% CI,
1.03-2.16 P ¼ 0.03
OR, 1.26 95%
0.92-1.71 P
8-30 days before surgery
(n ¼ 2639)
OR, 0.95 95% CI,
0.69-1.31 P ¼ 0.77
OR, 0.93 95%
0.73-1.18 P
 31 days before surgery
(n ¼ 44,269)
Reference Reference
CI, conﬁdence interval; MI, myocardial infarction; OR, odds ratiohypertension. Dunn et al. demonstrated that although initial
acute intravenous b-blocker administration decreased cardiac
output and increased peripheral vascular resistance, these
changes are attenuated after 4 weeks of ongoing oral therapy.26
Third, residual unmeasured confoundingmay have explained,
in part, the increased 30-day mortality among individuals who
underwent surgery shortly after starting b-blockade therapy.
Speciﬁcally, our databases lacked some relevant information,
such as disease severity or indications for b-blockade. None-
theless, it is unlikely that unmeasured confounding is the only
explanation for our ﬁndings, especially because it would have
also biased the risk of 1-year mortality, which was not
increased after 1-7 days of preoperative b-blockade. In
contrast, true adverse hemodynamic effects from acute
b-blockade could have plausibly affected only 30-day mor-
tality. Indeed, selective effects on short-term vs long-term
mortality have been observed for interventions affecting
perioperative hemodynamic stability. For example, 30-day
mortality is higher after open vs endovascular abdominal
aortic aneurysm repair, yet the 2 techniques have similar risks
of long-term mortality.27-29
Our study warrants comparison with the POISE trial,9 as
well as the 2 previous observational studies.12,13 Our ﬁndingsutcomes
MI 1-year mortality 30-day ischemic stroke
CI,
¼ 0.15
OR, 1.06 95% CI,
0.84-1.35 P ¼ 0.62
OR, 1.37 95% CI,
0.64-2.94 P ¼ 0.41
CI,
¼ 0.53
OR, 0.90 95% CI,
0.75-1.07 P ¼ 0.22
OR, 1.14 95% CI,
0.65-2.02 P ¼ 0.64
Reference Reference
Figure 2. Kaplan-Meier curves describing time to mortality within 1 year after major elective noncardiac surgery stratiﬁed by duration of preoperative
b-blocker therapy. Percentage of patients dying of all causes among individuals who were receiving b-blocker therapy before major elective
noncardiac surgery are seen. The ﬁgure represents unadjusted Kaplan-Meier curves for 3 categories deﬁned by the interval from b-blocker initiation
to surgery.
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the increased 30-day mortality among patients starting
b-blocker therapy immediately before surgery. Conversely,
although b-blockers reduced MI in the POISE trial, our
adjusted analyses found an increased risk of MI that bordered
on statistical signiﬁcance (P ¼ 0.15) among individuals
receiving 1-7 days of preoperative b-blockade. These seem-
ingly contradictory results may be explained, in part, by dif-
ferences in the comparisons being made. Speciﬁcally, although
the POISE trial compared b-blockers against placebo, all in-
dividuals in our study were receiving b-blockers, and the
comparisons pertained to different timing of b-blocker initi-
ation. To date, there has been no direct randomized com-
parison of short vs long duration of preoperative b-blocker
therapy. Qualitative evaluation of relevant individual RCTs
suggests the possibility that risks of postoperative MI could be
higher after shorter vs longer durations of preoperative
b-blocker therapy. For example, when compared with pla-
cebo, the POISE trial b-blocker protocol caused a moderate
reduction in MI (hazard ratio, 0.73; 95% CI, 0.60-0.89).
Conversely, in comparison with open-label control, prolonged
periods of preoperative b-blocker therapy caused large re-
ductions in postoperative nonfatal MI or cardiac death in both
the DECREASE-I (relative risk, 0.09; 95% CI, 0.02-0.37)
and DECREASE-IV (hazard ratio, 0.34; 95% CI, 0.17-0.67)
trials.5,30 Nonetheless, these comparisons should be viewed
cautiously because the results of the DECREASE-I and
DECREASE-IV trials may be exaggerated because of their use
of open-label control31 and early termination of the trials.32Previous observational studies that directly evaluated the
timing of preoperative b-blocker initiation included single-
centre cohort studies from the Netherlands and Canada.12,13
Our ﬁndings are consistent with these previous studies in
that all studies demonstrated worsened outcomes among in-
dividuals who received b-blocker therapy for < 7-10 days
before surgery. However, these previous studies had some
differences with respect to the types of adverse events seen in
patients receiving < 7-10 days of preoperative b-blockade. For
example, in the previous studies, mortality rates in this sub-
group were not signiﬁcantly different, whereas rates of post-
operative troponin elevation were increased.13 In our study,
such individuals experienced signiﬁcantly increased rates of
30-day mortality and a possible trend toward increased post-
operative MI. These differences may be explained by the
increased statistical power for assessing differences in 30-day
mortality in our present study and improved ascertainment
of MI in the previous cohort studies. Speciﬁcally, there were
relatively few 30-day deaths in the previous cohort studies,
whereas our present analysis included 839 such events.
Conversely, the previous cohort studies ascertained MI based
on recorded troponin measurements, whereas we relied on less
accurate International Classiﬁcation of Diseases (ICD)-10
diagnostic codes.
Our ﬁndings suggest that if b-blocker therapy is deemed
warranted in a patient awaiting major elective noncardiac
surgery, therapy should preferentially be started  8 days
before surgery. Nonetheless, our study does not address
whether 8-30 days of therapy is superior to no therapy at all,
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meta-analysis of high-quality RCTs has shown that preoper-
ative b-blockade, regardless of its duration, reduces the risk of
MI,33 the dilemma that clinicians face is the potential for
associated increases in perioperative mortality and stroke. The
consistency of ﬁndings in our present analysis and previous
cohort studies point to the need for an adequately powered
placebo-controlled RCT to determine whether a moderate
and clinically feasible duration of titrated preoperative
b-blocker therapy (ie,  8 days) can achieve a reduction in MI
without simultaneous increases in mortality or acute stroke.
Such a trial is urgently needed, especially because periopera-
tive MI remains frequent and prognostically important,34
b-blockers do reduce the risk of these complications,9,33 and
b-blockers remain an easily accessible cardiovascular medica-
tion for most perioperative clinicians.
Several limitations of our study should be considered. First,
in-hospital b-blocker use was not captured by our databases.
Thus, we were not able to assess whether patients continued
to receive b-blocker therapy during their hospital stays. In
addition, our analysis excluded individuals who started
b-blocker therapy immediately before surgery after hospital
admission. Nonetheless, such regimens have already been
evaluated by the POISE trial. Second, despite the large sample
size of this multicentre study, its statistical power to address
some relevant questions was limited. For example, we could
not further categorize the subgroup of patients with 1-7 days
of preoperative b-blocker therapy to determine the risks
associated with even shorter periods of preoperative b-blocker
therapy. In addition, the low incidence of postoperative
ischemic stroke limited statistical power to compare different
durations of preoperative b-blocker treatment with respect to
risks of this important complication. Notably, the overall
number of strokes within the cohort (n ¼ 218) meant that
estimates from the relevant regression model were not biased.
The ratio of outcome eventsetoepredictor variables within
the model exceeded the minimum 10:1 ratio recommended to
minimize bias when estimating coefﬁcients in logistic regres-
sion models.35 Nonetheless, the low absolute number of
ischemic strokes among individuals who received < 31 days of
preoperative b-blocker therapy resulted in associated odds
ratios with wide and imprecise conﬁdence intervals. Third,
our data sources did not capture some relevant detailed clinical
information. For example, the databases did not capture
physiologic information (eg, heart rate), laboratory test results,
speciﬁc postoperative complications (eg, hypotension), or
causes of death, all of which might have provided insights into
the mechanisms whereby very recent initiation of preoperative
b-blocker therapy led to increased 30-day mortality. Fourth,
as with any observational study, our study by itself does not
prove a causal relationship between a very short period of
preoperative b-blocker therapy and increased 30-day mortal-
ity. Our hypothesis-generating ﬁndings therefore warrant
conﬁrmation by other multicentre observational studies, as
well as deﬁnite evaluation in an adequately powered RCT.Conclusions
In this population-based study, initiation of oral b-blocker
therapy within  7 or days before major elective noncardiac
surgery was associated with signiﬁcantly increased 30-daymortality. In concert with similar ﬁndings in previous cohort
studies, these present ﬁndings point to the need for
a multicentre placebo-controlled RCT to determine whether
a moderate duration of preoperative b-blocker therapy (ie, 
8 days), which is titrated to an optimal dose, can prevent
perioperative cardiac complications, mortality, and acute
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